| Atrial Fibrillation
Sotylize vs Eliquis
Side-by-side clinical, coverage, and cost comparison for atrial fibrillation.Deep comparison between: Sotylize vs Eliquis with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsEliquis has a higher rate of injection site reactions vs Sotylize based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Eliquis but not Sotylize, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Sotylize
Eliquis
At A Glance
Oral
Twice daily
Class II/III antiarrhythmic
Oral
Twice daily
Factor Xa inhibitor
Indications
- Ventricular arrhythmia
- Atrial Fibrillation
- Atrial Flutter
- Atrial Fibrillation
- Deep Vein Thrombosis
- Pulmonary Embolism
- Venous Thromboembolism
Dosing
Ventricular arrhythmia Initial 80 mg orally twice daily; increase by 80 mg/day every 3 days to a maximum 320 mg/day, with therapeutic response typically at 160-320 mg/day in two or three divided doses.
Atrial Fibrillation, Atrial Flutter Initial 80 mg orally twice daily; increase by 80 mg/day every 3 days provided QTc <500 msec; most patients respond at 120 mg twice daily.
Atrial Fibrillation 5 mg orally twice daily; 2.5 mg twice daily in patients with at least 2 of the following: age >=80 years, body weight <=60 kg, or serum creatinine >=1.5 mg/dL.
Deep Vein Thrombosis (prophylaxis, hip or knee replacement) 2.5 mg orally twice daily initiated 12-24 hours post-surgery; 35 days for hip replacement, 12 days for knee replacement.
Deep Vein Thrombosis, Pulmonary Embolism (treatment) 10 mg orally twice daily for 7 days, then 5 mg twice daily.
Deep Vein Thrombosis, Pulmonary Embolism (recurrence reduction) 2.5 mg orally twice daily after at least 6 months of treatment for DVT or PE.
Venous Thromboembolism (pediatric) Weight-based dosing orally twice daily following at least 5 days of initial anticoagulant treatment; doses range from 0.3 mg to 10 mg twice daily based on weight tier.
Contraindications
- Baseline QT interval >450 msec
- Sinus bradycardia, sick sinus syndrome, or second and third degree AV block without a functioning pacemaker
- Congenital or acquired long QT syndromes
- Cardiogenic shock or decompensated heart failure
- Hypokalemia
- Bronchial asthma or related bronchospastic conditions
- Hypersensitivity to sotalol
- Active pathological bleeding
- Severe hypersensitivity reaction to apixaban (e.g., anaphylactic reactions)
Adverse Reactions
Most common (>=2%) Fatigue, bradycardia, dyspnea, proarrhythmia, asthenia, dizziness.
Serious Sustained ventricular tachycardia/ventricular fibrillation, Torsade de Pointes.
Postmarketing Emotional liability, slightly clouded sensorium, incoordination, vertigo, paralysis, thrombocytopenia, eosinophilia, leukopenia, photosensitivity reaction, fever, pulmonary edema, hyperlipidemia, myalgia, pruritus, alopecia.
Most common (>=1%) Epistaxis, contusion, hematuria, menorrhagia, hematoma, hemoptysis, rectal hemorrhage, gingival bleeding, nausea, anemia.
Serious Major bleeding including intracranial hemorrhage, gastrointestinal bleeding, and fatal bleeding.
Pharmacology
Sotalol is a non-cardioselective beta-adrenoreceptor blocker (Vaughan Williams Class II) with cardiac action potential duration prolongation (Class III) antiarrhythmic properties; it slows heart rate, decreases AV nodal conduction, and increases refractory periods of atrial and ventricular muscle and conduction tissue.
Apixaban is a selective inhibitor of factor Xa (FXa) that does not require antithrombin III for antithrombotic activity; by inhibiting free and clot-bound FXa and prothrombinase activity, it decreases thrombin generation and thrombus development without directly affecting platelet aggregation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Sotylize
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (0/12) · Qty limit (0/12)
Eliquis
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Sotylize
- Covered on 4 commercial plans
- PA (3/8) · Step Therapy (0/8) · Qty limit (0/8)
Eliquis
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Humana
Sotylize
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Eliquis
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availablePAF Co-Pay Relief: Cardiac Arrhythmias
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Eliquis.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
SotylizeView full Sotylize profile
EliquisView full Eliquis profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.